Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Spotcast

Spotcast artwork

Dr Marcus Butler: Medical Oncologist at the Princess Margaret Cancer Centre Toronto and is Associate Professor at the University of Toronto.

Oct 1, 202644 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of Spotcast, I am joined by Dr. Marcus Butler the Multidisciplinary Disease Site Lead for Melanoma/Skin Oncology and the Medical Director of Solid Tumor Cellular Therapy. He is also the Clinical Director of the Princess Margaret Tumor Immunology to Immunotherapy Program (TIP) and Clinical Director for the Centre for Integrative Immune Analysis. He is an Associate Professor in the Departments of Medicine and Immunology at the University of Toronto and is Co-chair for the Melanoma Site at CCTG (Canadian Cancer Trials Group). Today we discuss Melanoma, the developments in its treatment over the last 20years and Dr Butler gives an overview of how drugs are approved in Canada Resources: Melanoma Patient Guide Melanom-What-You-Need-to-Know-Melanoma-Canada.pdf Clinical Trial Finder Melanoma Canada Understanding Rare Melanomas & Skin Cancers - Melanoma Canada Canada's Drug Agency | CDA-AMC INESSS: inesss.qc.ca Support and Resources - Melanoma Canada

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00The development of statements over the last 20 years of our given over the year in Canada described and share the episode of it. Thank you, Dr. Butler, for joining me. You're very welcome to the podcast. And thank you for taking the time to have a conversation with me about all things melanoma and its treatments. Before we kick off the podcast episode, I was wondering if you could tell us a little bit about yourself, your role as a medical oncologist, and kind of your day-to-day job in melanoma.

SPEAKER_02Hi. So yeah, thank you so much for the chance to talk with you today. And it's really great to chat with you. So I'm a medical oncologist. That's a type of doctor who is trained in internal medicine in my case, and then subspecialize in medical oncology. Medical oncology is a field of internists that treat patients with cancer with drugs, basically.

SPEAKER_02And we're interested in either giving drugs to prevent relapse of the cancer or to give drugs in patients where surgery and radiation are no longer possible to achieve cure so that we can treat patients.

SPEAKER_00Great. Thanks for that, Dr. Butler. And I suppose medical treatment has changed dramatically over the past decade. What do you think has been the biggest change you've seen in your career?

SPEAKER_02So yeah, melanoma has probably had the biggest change in its treatment uh over the last uh it's actually been more than 10 years, I would say, because uh because we've been lucky enough to be at the forefront of a lot of the development of new therapies. But um maybe 15, 20 years ago, the only treatments we had for melanoma were um treatments with um chemotherapy in patients who had advanced disease, or for patients who we were trying to prevent relapse, we had a drug called interferon.

SPEAKER_02There was also a subgroup of patients who would be treated with uh uh a drug called IL-2, intaleucin-2, it's also called Aldisleucin, which was a highly toxic regimen that would be used in a subpopulation of patients with melanoma or kidney cancer, and you could have some patients who would have a long-term improvement. But, you know, what that meant was if you had metastatic melanoma, um, your chances of being alive five years later was less than 10%.

SPEAKER_02In fact, your average life expectancy was around 11 months uh for patients. And if you had disease that had gone to the brain, it was actually less than six months. The the outcomes were really terrible. There were patients who survived, but um there really weren't that many patients, and we really didn't understand why some people did better than others. Uh, and we would have some examples where patients would have their cancer grow and then it would disappear.

SPEAKER_02So everybody uh in the distant past thought that melanoma was a weird disease, that maybe the immune system was important, especially that drug IL-2 or aldisleucin, which is a type of immunotherapy drug, and could achieve responses in a minority of patients. Like, yeah, there's something there. And then um 20 years ago, the drug IplilMab was developed and uh ended up getting approved and showed that you could improve the overall survival.

SPEAKER_02Um, just prior to that, there were multiple studies and uh meta-analyses. That's where you put multiple studies together and showed that basically nothing had worked for 30 years of research, and then all of a sudden we had a drug that worked. And uh then after the approval of IpalilMab, we had the anti PD-1 drugs, uh Navola Mab and Pembrolizimab achieve referral about five years later. So these drugs have been the most remarkable in terms of providing options for patients where we achieve what I think are probably cures, where patients with uncurable disease have been treated with these drugs, and a proportion of patients never relapse, at least not so far, and then we're getting out to 15, 20 years.

SPEAKER_02Also, around the same time, we had targeted therapy that becomes available, so patients had new options for therapy. And also, actually, just before the IPLMAB, um, there was some success in till therapy, tumor infiltrating lymphocyte therapy, uh, but I'm sure we'll get into it a little bit more. But that it kind of took a back seat in the development of the immune checkpoint inhibitors and targeted therapy before lifolusyl and and till therapy has has moved forward in Canada.

SPEAKER_00And an amazing time, I'm sure, to be to be involved. And as you say, remarkable drugs being being developed. I was wondering, Dr. Butler, if you could, you know, we hear the terms immunotherapy and targeted therapy quite a lot, but if you could maybe just quickly uh and then and then in simple terms maybe explain the difference between immunotherapy and targeted therapy.

SPEAKER_02Yeah, so I think let's start with targeted therapy. So targeted therapies, oh well the term targeted therapy uh was coined because we are targeting a particular mutation that's present in a patient's cancer. That's all it means. So a targeted therapy could be pills, it could be IV, it could be whatever, but it's targeting a particular mutation that's found in the patient's cancer.

SPEAKER_02And uh melanoma is kind of the poster child for targeted therapy because uh we identified, uh not we, but as a field, uh many other people smarter than myself identified mutation that's common in about 40% of melanoma patients, uh BRAF mutation, and found that there was a class of drugs that could target that particularly mutated uh protein, and that the drugs had specificity for that mutation and then achieved a good clinical response.

SPEAKER_02There are also targeted therapies that will target a pathway that's activated in a per particular cancer cell, but those types of medicines are less specific for the tumor and will, but they, you know, they target the pathway that's uh abnormal in the patient cell. So immunotherapy basically the term just means a drug that enhances the immune response against the cancer.

SPEAKER_02And um, there are all kinds of immunotherapies that are available, types of proteins called cytokines that activate the immune system. There are cells that are immune cells that is a type of immunotherapy. There are drugs that can activate patients' immune cells, and some of those are called bispecific T cell engagers. But when we're with a melanoma patient in clinic and we talk about immune therapy, we're usually referring to uh the immune checkpoint inhibitors.

SPEAKER_02So that's drugs like ipalilimab, pemblyzimab, nivolimab. Uh these are monocle antibodies that are targeting an element of the immune system to activate the immune system in patients. And uh the reason why they're called immune checkpoint inhibitors is that uh basically in a in a normal immune response, we have activating parts of the immune system, and we also have suppressive arms of the immune system.

SPEAKER_02One of the suppressive arms that prevents an immune response from going haywire is uh a class of molecules called immune checkpoints. And these new drugs that have achieved such amazing results basically uh block the immune checkpoints. And when you block a blocker, you cause activation. So you know, one of the analogies that I think is useful is that the immune system is often kind of like a car in neutral, which where the engine is revved up, and uh sometimes you engage and the car goes fast, and if it goes too fast, you run into problems.

SPEAKER_02So it applies the brakes. And um it just so happens that we're able to relieve the brakes a little bit on the immune system so that we can treat the cancer, but the patient still does well. Sometimes a patient receives these drugs, has no side effects, and just has a cancer disappear. Sometimes we have side effects that involve the immune system attacking normal tissues. Um, and you know, unfortunately, it doesn't work in everyone, but it does work in a substantial proportion of patients.

SPEAKER_02So we use these drugs for people.

SPEAKER_00Thank you, uh Dr. for that explanation. I I I love that analogy, and I know um our what melanoma, what you need to know, but the talks more in depth around the different types of immunotherapy and targeted therapy. So I will link that in the notes of the the episode. And I know you've been uh contributor to that and that information. So I'll definitely want to read up a little bit more um around the different type of uh later and some exciting news or recently exciting news.

SPEAKER_00The announcement from Merck and Moderna about the MRN vaccine. Um I was wondering if you could explain to your listeners what exactly is that, what how does it work, and and what will that look like for patients?

SPEAKER_02Yes, so um basically Merck and Moderna teamed up to see whether a mRNA vaccine could be added to pembrolizimab as a treatment to prevent uh melanoma from returning, from relapsing. The and in a phase two study, uh Moderna's vaccine was successful in preventing relapse.

SPEAKER_02There weren't enough patients to be statistically certain enough to get approval, so they did a randomized study with larger number of patients in multiple jurisdictions around the world, and that study uh apparently is positive. So I say apparently because all we know is a press release. There is not any data. Um when when a company uh does a big phase three study, they're required uh to release the data as soon as they know, uh, and that prevents insider trading.

SPEAKER_02So that's all we really know is that there's a very promising treatment in the phase three. Uh it's positive. What we don't know is how positive it is. Is the degree of meeting the endpoints really, really good or just good? And um we'll find out when the data is released. Most of us guess that the data is going to be presented at uh in Madrid at the uh end of October at the European medical oncology meeting, the ESMO.

SPEAKER_02So what this Moderna vaccine is, it's a it's basically an mRNA vaccine. It's similar to the COVID vaccine, but instead of putting in the bits of the COVID virus, they put in bits of mutations that are found in the patient's own melanoma cells. So in order to make this vaccine, uh they take slides from the patient's melanoma that's been removed in a patient who's had surgery.

SPEAKER_02They're at high risk of relapse, um, so they're eligible for the study. The companies then did sequencing to identify mutations uh present in the patient's melanoma, and then they generated uh small sequences that are inserted into the vaccine, the mRNA vaccine, which is then used to treat the patient. So one person's bespoke uh vaccine, which they're calling intismeran, um would work for that patient, probably, but probably wouldn't work for another patient.

SPEAKER_02So it's it's truly individualized therapy, and that's then combined with pembrolyzimab, which is a treatment that's used to prevent relapse from melanoma. This study is one of the first in a series of studies, Merck and Moderna are collaborating on multiple other studies and other diseases to see if uh this approach will be useful. A lot of times patients will ask, well, can I have a vaccine to treat my cancer that's not surgically curable?

SPEAKER_02And the answer is we don't know. There are studies to look at this question. Uh the studies are are not yet mature. Uh, they're being investigated. There is a first-line uh study with this vaccine in patients with metastatic melanoma that uh some centers are participating in. Um, but we're we're waiting on on the results of of those studies.

SPEAKER_00Amazing. Like the vaccine you mentioned there, you know, Dr. is tailored to the patient. It's going to be bespoke. Um and with that, I you know, even by deciding that you you can sense that there'll be a much higher cost to produce that type of therapy, that type of treatment for patients. A drug approval for that, you know, I think that can, you know, and another country can take it a long time from when it gets completed that uh fees, you know, free trial to when it is available to patients.

SPEAKER_00Um why does it take so long to get to from trial to patients? And is cost one of the biggest barriers to that?

SPEAKER_02So number one is the provinces are responsible for um funding uh drugs as part of the the provincial health plan. And the provinces have, I think, universally signed up to approving drugs uh for reimbursement, uh, because this is how we pay for drugs. So like hospitals are not public hospitals, they're they're not owned by the government, but they're supported by the government.

SPEAKER_02So it is truly reimbursement and insurance. So basically, if you get a treatment at a cancer center, the the cost of that treatment is reimbursed by the government, and they want to practice evidence-based medicine. So the ways that um we uh will treat patients is we basically find out what the province will fund. And the questions the province has, well, first of all, you have to give a drug that's that is Health Canada approved for some indication.

SPEAKER_02Now you can give treatments that are not strictly on label, in other words, the indication is is is an off-label indication. Uh, but there's also another process that looks at the uh and advises the provinces on whether to fund a particular drug, and that's called part of the health technology assessment, which is actually completely separate from Health Canada. And that's why you can have a Health Canada approval, but yet there's a delay in the provinces making a decision about funding because the provinces want to have their health technology assessment.

SPEAKER_02Health Canada approval means safe and effective, but it's a kind of a question that's in isolation. It doesn't mean safe and effective, and we must fund this particular drug because there might be another safe and effective drug that's better. So the provinces have asked for uh the these health technology assessments to occur first. In uh in Quebec, there's uh an agency called ENES that looks at these questions.

SPEAKER_02In most of the other uh provinces uh we use uh an agency called Canada's Drug Agency or CDA. So the health technology assessment uh involves input from the drug manufacturer. We provide uh you know physicians uh and oncologists are allowed to provide input and perspective, uh, patients have a voice to provide input.

SPEAKER_02And the um but basically this the drug manufacturer provides a uh a data packet to uh Canada's drug agency, and then all of these inputs are reviewed, and then they come up with a recommendation on whether or not to uh re uh on whether or not the provinces should reimburse. So after that process, which can take about six months, then the provinces uh band together through an agency called uh uh uh Pan-Canadian Pharmaceutical Alliance, where they then negotiate with the manufacturer uh the conditions for uh funding the drug.

SPEAKER_02Um and that sometimes takes time. Sometimes that process can take years. So there are Health Canada approved drugs that are stuck in that Pan-Canadian Pharmaceutical Alliance negotiation, and that's uh uh that's an important issue. And you know, this is where the the health technology assessment is saying, well, you know, this safe and effective drug provides this amount of benefit, and then they're quibbling about how much the benefit is or not, and what is it worth, and those sorts of things.

SPEAKER_02And then after that process happens, then the provinces are uh make an independent decision whether or not to fund a drug. So you know, just because there's a recommendation to fund, just because the uh negotiations have concluded doesn't necessarily mean that the particular provinces has to uh fund. Um and you know, this is where patients and and uh citizens need to ask questions when it's not funded.

SPEAKER_02Um uh you know, why are there delays?

SPEAKER_00Yeah, thank you for that you know, great, I think great overview of the the drug approval process um uh in Canada. And you know, uh we do submit you know as part of the the health technology assessment to CDM and melanomach.

SPEAKER_00And you use the term stuff there before we know the Till Therapy has been half of Canada for the last year, but it's still not readily available to patients here in Canada. So gather your thoughts. I know you've been heavily involved in teletherapy and your view on its accessibility to patients.

SPEAKER_02Yeah, so TILTherapy has an interesting uh history. It's been a treatment under development since the 80s and 90s. And if it wasn't for immune checkpoint inhibitors, it probably would be used routinely in our practice. Um it I think it it was developed in the US by uh Dr. Steve Rosenberg, um, and he had really promising results.

SPEAKER_02There was a lot of argument as whether you had patient selection um as the reason why patients did well. So there was some of those concerns. Um, but ultimately uh there were some randomized data that showed uh better outcomes. And uh for uh the Europeans did a randomized study uh which was positive that sort of cemented the idea that TIL therapy had a role even after uh immune therapy uh fails the patient.

SPEAKER_02And and then this company Iovance uh developed uh lifelusyl, which is a type of tumor infiltrating lymphocyte therapy, and it has approval. It um you know, if you go on the CDA website, you can look at the dates for when uh there was um public um review. It's all there. And the the call for input for clinicians and uh patient opinion regarding life alusal was a little delayed from the time of Health Canada approval.

SPEAKER_02That you know, that's the situation is that those uh the health technology assessment occurred a little bit later than Health Canada approval. And this is one of the challenges for smaller biotechs because they may not prepare, be prepared the way Merck is uh for um getting uh a review. In fact, I haven't gone on, I it's a good question. I should go on to the website and see if Intismaran shows up on the CDA website because it's no, you know, these things are not advertised, they just sort of show up on the website and it's publicly there.

SPEAKER_02It's just it's kind of like looking um uh in the newspaper for uh real estate stuff when you know it's it's just there and announced. So anyway, if you're interested, it's probably something good to do. So as I mentioned, it's a six-month review. That process is happening with Iovance um uh with uh Life Alusal, brand name and tag the. And uh we should be getting some uh public uh opinions in November regarding recommendations.

SPEAKER_02And after that process, I think early December, the final recommendation is expected. Uh, then uh there'll be that uh uh negotiation with the Pan-Canadian Pharmaceutical Alliance. Now we didn't really talk about what is till therapy. So till therapy again is a bespoke treatment, and in this case, instead of taking a paraffin uh you know, slides from a prior surgery, you need to actually take out a tumor, at least a cubic uh 1.5 centimeter uh cubic um size tumor that needs to be harvested from a patient live and then sent for manufacturing.

SPEAKER_02So that piece of tumor is taken to the laboratory where uh the tumor is uh fragmented and then bathed in high dose IL2 and other goodies to grow up the T cells in uh from that tumor. Those T cells are then expanded to large numbers and then are infused as a treatment for patients.

SPEAKER_02Um it's a quite complicated process because, in order for the lifelusyl to work, you have to give chemotherapy to the patient to make room. That's called lymphoding chemotherapy. Then you put in the T cells from the TIL therapy, and then you have to give more uh aldusleucin, which is the IL-2 treatment that helps the T cells grow and expand. And in order for patients to receive that, they not only have to undergo a surgical procedure about five weeks prior to treatment, but then they also have to be admitted to the hospital for the infusion.

SPEAKER_02So it's a complicated process. Currently, for standard TIL therapy, the only option for receiving this treatment is as part of a clinical trial that's currently a first-line trial. And most patients end up wanting to participate or to receive standard immunotherapy, uh, immune checkpoint immunotherapy, because it's faster than the delays that result in treatment with the upfront till therapy.

SPEAKER_02Um there is a little bit of movement where combination immunotherapy is available in later lines, so maybe more patients will be willing to do upfront till. But the real role uh for the approval is actually for patients who've had previous treatment that hasn't worked, and then they receive till therapy, and that's the resulted in the Health Canada approval, and hopefully it'll become available uh for commercial uh use um in the coming months.

SPEAKER_00Thank you for that. Um and in your opinion, Dr. Butler, compared to other countries US, UK, Europe is the the drug approval process similar here in Canada, or do you think it is longer?

SPEAKER_02Well, for the United States, you get approvals from uh FDA and it gets uh the basically Medicare needs to list it. So it they don't it doesn't undergo the same second review process that is performed in Canada. Now there are actually some positives associated with that.

SPEAKER_02One of the positives is that you can have a CDA review on and an ENES review on a treatment that's actually an off-label indication, and you can get an advice to the provinces to fund something that is truly off-label, and that's an advantage, where as the process for off-label indications in the US is there, but it's a little bit more, it's it's something called East NCCN guidelines, which is a little less structured.

SPEAKER_02Uh you know, actually, I'm not an expert on NCCN, but it there are some complexities to NCCN that people criticize. So it's like it's too open. Um but so that has some advantages to our current system. The uh the delays um are there. I would not say that we're worse off than Europe. I think we're quite similar to Europe and the UK.

SPEAKER_02Um in fact, sometimes we can be much faster. We can be faster than many of our European and UK colleagues. Um the the issue about uh slowness, some of it is within, yes, there are delays in review, but it's easy to finger point and you know to know exactly what are the obstacles. It you know, it sometimes is related to the drug manufacturer where they don't what we call launch a drug right away.

SPEAKER_02They may hold back, and some of that has to do with politics, um, and some of it has to do with their expectation for whether the drug will receive approval, um, and which has to do with the guidelines for Health Canada uh approvals. And the fact that the HTA process is not hardwired into a Health Canada approval is probably an Achilles heel for our system because if you get a Health Canada approval, there's not an automatic health technology assessment that kicks in.

SPEAKER_02And um that means that you can have a delay in submissions. Um and but it that's not absolutely necessary to have a delay in submissions. Um, what the big companies might do is they start their health technology assessment early when while they're anticipating that there's going to be a uh a health Canada approval. And you know, but that's at risk because there may not be a health canada approval.

SPEAKER_02Anyway, that is something that might be able to be fixed. I think figuring out a way to speed up the health technology assessment would be helpful. I think where we do see a lot of things get held up is during that uh that PCPA or Pan-Canadian Pharmaceutical Alliance negotiation. Um, and you know, money makes the world go round. So this is an issue. Uh, but you know, uh as citizens, we want to have value and and um that is uh part of the process.

SPEAKER_02I think where we really have some challenges is how do we navigate uh approvals for rare conditions? Because the level of evidence for a rare condition is we well, it's uncertain. It's like what level of evidence would be good enough if it's a rare condition. And if we're gonna hold up the same level of certainty that we do for a more common condition, is that fair to patients with rare conditions?

SPEAKER_02Because that means that the rare condition may never have that level of evidence. So I think we're still, I think the the decisions that are made for uh approvals of expensive drugs is still in the development phase. And I know that the people at CDA uh and Health Canada are hard at work to try to figure out ways to to streamline things.

SPEAKER_00Absolutely. And yeah, there's there's still still work to do. Um and that does lead me nicely into um the the rare melanoma space. Uh Dr. Butler, I'm wondering, you know, obviously with the M or N vaccine, you know, that announcement, exciting news coming for that for melanoma patients in the rare melanoma space. Um are there any new developments happening and to your knowledge?

SPEAKER_02So for rare melanomas, that that would include um acral melanoma and mucosal melanomas, which are essentially pretty much treated like standard melanomas. Um they're close enough with those that they're included, uh, but they are different in biology and may require different treatments. And I think we need to do better at uh providing those patients with specialized treatment options.

SPEAKER_02Those types of tumors are kind of evenly distributed geographically, and patients tend to be treated locally by their medical oncologist because basically there aren't any special treatments for those patients that are different, but they may require different treatments, and there may be new uh treatment options for those patients in the future. Right now, not anything specific, um, although we've had there's recently concluded an adjuvant study that gave patients immunotherapy along with uh Cabazant in a clinical trial.

SPEAKER_02Um, for uvial melanoma, that's a rare type of cancer of the eye. Um, and about uh five to six patients per million per year develop this condition. And patients have a high risk of relapse where the disease spreads to other organs, uh, most commonly the liver. For this uh uh condition, um, there are some very promising uh results.

SPEAKER_02Um the the drug uh Derovacertib combined with uh a lung cancer drug called chrisotnib has promising early results uh that have been presented. Um and we're hoping to have uh uh an FDA approval sometime this fall. Um the company that is managing uh Derovasertib in Canada is a company called Servier, and uh they uh are uh hoping to have overall survival uh data uh to move forward with their submissions to Health Canada.

SPEAKER_02This where this is where we get into another uh uh complexity where the drug company might feel like they need overall survival data before submitting as opposed to using a what we call a surrogate endpoint. That's called progression, in this case, progression-free survival. So the amount of you give the drug and patients have no growth of the cancer, that will result in an FDA approval. The company is feeling like they need to have overall survival data to submit to Health Canada, that results in delays.

SPEAKER_02We've been advocating for them to move forward with the Health Canada approval quicker. You know, we're waiting to see what happens.

SPEAKER_00And as you rightly said, with those rare types of melanoma, the smaller population of those diseases, it makes that makes that hard as well for for companies to get approval. But thank you for touching on all of that, uh Dr. Poller. I have a couple of questions I just want to finish off before I let you go. Um in your opinion, what is the biggest unanswered question in melanoma research that you would love to see solved?

SPEAKER_02Well, I think the biggest question we have is why do some patients uh do really well with our current treatments, but others don't? And how can we identify the patients who are not going to benefit from treatment? How can we identify them earlier and so that we can get them on a different type of treatment? Uh, because right now, basically, we give the pay we give every patient the same treatment.

SPEAKER_02We may have some assays that kind of point us in a different direction, but we don't have treatment algorithms that are biomarker-based that really firmly tell us to treat a particular patient in a different way, uh, different than than another patient. So I would I would like these biomarkers, and I would like to be able to identify patients who are not going to benefit from it from my therapy so that I can put them on something else, even if it's experimental.

SPEAKER_02I think that answered your question.

SPEAKER_00Yeah, absolutely. And just finally, uh Dr. Butler, for those patients who are newly diagnosed with melanoma, you know, what would you like them to know, or what advice would you give them about how quickly the field of melanoma is changing? And what you know piece of hope would you give to patients who are being diagnosed to death?

SPEAKER_02Yeah, so I mean I think the most important thing to understand is that the vast majority of melanomas that are diagnosed are caught early and are cured by the surgeon or the even the dermatologist within SI2 disease and plastic surgery. So I think that's great. And that our evidence, our our uh attempts to uh identify uh melanomas early and get them treated, I think, are are really uh quite successful.

SPEAKER_02And you know, I applaud the work that Melanoma Canada has done with the mobile beal to increase awareness and and to get patients to treatment sooner than later. The for patients who have advanced disease, you know, every year we're finding out new treatments and new approaches to try to uh improve outcomes. And there's also persistent advocacy by uh by uh patient groups to uh improve access and to make sure that patients have the best options for therapies.

SPEAKER_02Um and you know that is is really uh great, so that therefore patients really have a lot of hope that even if they have a diagnosis that in another era uh would mean there was really no chance of long-term survival. For I mean, it was never no chance, but very low chance for long-term survival, that's a completely different story now. Um, and we do have uh quite good results.

SPEAKER_02But you know, uh I think uh in terms of new treatments for patients who have developed resistant disease, we um you know there are there are new treatments uh with different, more innovative types of cell therapies are currently being developed. Uh new uh uh drugs that uh are called T cell engagers are being developed, and there really are a lot of new approaches to try to uh enhance the immune response and and and treat patients.

SPEAKER_00Thank you so much, uh Dr. Butler. Um thank you for joining me, for uh giving your time up. We are we are honored to have uh uh leader in medical oncology join us on the podcast. So thank you so much for your for your time, for sharing your your your knowledge, your expertise, and for talking us through all of the treatments and the processes and explained and also now to our leftists um we're gonna for your time and for all of the e2 for our mail on the community and and your continued support for Mel on Wikinada.

SPEAKER_00So thank you for joining us.

SPEAKER_01I'm sure that we'll it's been a lot of fun and uh you take care of it.

SPEAKER_00Thank you for listening to the podcast. We will be sure to everyone.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Melanoma Patient: Kitty Brown

    Nov 5, 202634 minAudio

    In this episode of Spotcast, Kitty Brown joins me to share her journey with stage 4 metastatic melanoma - from her diagnosis during the COVID-19 lockdown in 2020 to navigating vulnerability, finding acceptance, and...

    Credit the people on this episode

  2. Dr Mark Kirchhof: Head of the Division of Dermatology at the University of Ottawa and The Ottawa Hospital

    Sep 3, 202626 minAudio

    In this episode of Spotcast, I am joined by Dr Mark Kirchhof, Head of the Division of Dermatology at the University of Ottawa and The Ottawa Hospital. Dr Kirchhof shares information about all things’ dermatology -...

    Credit the people on this episode

  3. Melanoma Patient Allan Buium

    Jul 2, 202628 minAudio

    In this episode of Spotcast, I’m joined by Allan Buium, who shares his personal melanoma journey. We talk about his diagnosis, the highs and lows of immunotherapy, managing its side effects, and his experience...

    Credit the people on this episode

  4. Marie Eve (KRABĒO) Transforme un diagnostic de Melanome en Mission

    Jun 3, 202637 minAudio

    In this episode of Spotcast, Melanoma Canada Board Chair Dr. Mario Chevrette is joined by Marie Eve Richard Tougas for our first French episode. Dans cet épisode de Spotcast, le Dr Mario Chevrette, président du conseil...

    Credit the people on this episode

  5. Dr Sheila Garland - Sleep and Cancer

    May 6, 202632 minAudio

    In this episode of Spotcast, I am joined by Dr Sheila Garland, Clinical Psychologist and Professor of Psychology and Oncology at Memorial University of Newfoundland. Dr. Garland conducts psycho-oncology and behavioural...

    Credit the people on this episode